Bryxta 400 Injection
  1. Home
  2. Pharma Products
  3. Cadila Healthcare Ltd
  4. Bryxta 400 Injection

Bryxta 400 Injection

Bryxta 400 Injection contains bevacizumab, a monoclonal antibody used in the treatment of several types of cancer. It is supplied as 400 mg in 16 mL and is administered by intravenous infusion under medical supervision. Bevacizumab works by blocking VEGF, which helps reduce the formation of new blood vessels that support tumor growth.

BUY NOW

Category

Bryxta 400 Injection may be used with other anticancer medicines for metastatic colorectal cancer, non-small cell lung cancer, kidney cancer, ovarian cancer, cervical cancer, and other approved indications. By inhibiting vascular endothelial growth factor, bevacizumab can restrict the blood supply needed by tumors to grow and spread. The medicine should be administered by a qualified healthcare professional according to the prescribed chemotherapy protocol. Patients may require monitoring for blood pressure changes, bleeding, infusion reactions, and other treatment-related complications.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 400 mg
Concentration 25 mg/mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Pack Size 1 Vial, 16 mL

Product Also Known As

Bryxta 400 Injection, Bryxta 400 mg Injection, Bevacizumab 400 mg Injection, Bevacizumab 400 mg/16 mL Injection, Bryxta Bevacizumab Injection, Anti-VEGF Cancer Injection